Evidence map›Paper›PMID 33951076›Full record

ArticlePloS one2021

Incidence of dengue illness in Mexican people aged 6 months to 50 years old: A prospective cohort study conducted in Jalisco.

Rodrigo DeAntonio, Gerardo Amaya-Tapia, Gabriela Ibarra-Nieto, Gloria Huerta, Silvia Damaso, Adrienne Guignard, Melanie de Boer

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02766088 (A Cohort Study to Assess the Burden of Dengue Illness in Household Members From Selected Communities in Southeast Asia and Latin America), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02766088 naterminatednot on this map

A Cohort Study to Assess the Burden of Dengue Illness in Household Members From Selected Communities in Southeast Asia and Latin America

TypeinterventionalSponsorGlaxoSmithKlineRan2016 to 2018Enrolled1,750ConditionsDengue, Dengue VaccinesArmsBlood sample collection
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Rodrigo DeAntonioVaccines, GSK, Panama City, Panama.ORCID 0000-0003-2586-4115
Gerardo Amaya-TapiaDepartment of Infectious Diseases, Hospital General de Occidente, Zapopan, Mexico.ORCID 0000-0002-6747-1881
Gabriela Ibarra-NietoDepartment of Infectious Diseases, Hospital General de Occidente, Zapopan, Mexico.ORCID 0000-0002-3135-6347
Gloria HuertaVaccines, GSK, Mexico City, Mexico.
Silvia DamasoVaccines, GSK, Wavre, Belgium.
Adrienne GuignardVaccines, GSK, Wavre, Belgium.
Melanie de BoerVaccines, GSK, Rockville, Maryland, United States of America.ORCID 0000-0001-8495-8475
GlaxoSmithKline (Belgium) · BESecretaría de Salud de Jalisco · MXGlaxoSmithKline (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe burden of dengue virus (DENV), a mosquito-borne pathogen, remains difficult to assess due to misdiagnosis and underreporting. Moreover, the large proportion of asymptomatic dengue cases impairs comprehensive assessment of its epidemiology even where effective surveillance systems are in place. We conducted a prospective community-based study to assess the incidence of symptomatic dengue cases in Zapopan and neighboring municipalities in the state of Jalisco, Mexico.

methodsHealthy subjects aged 6 months to 50 years living in households located in the Zapopan and neighboring municipalities were enrolled for a 24-month follow-up study (NCT02766088). Serostatus was determined at enrolment and weekly contacts were conducted via phone calls and home visits. Participants had to report any febrile episode lasting for at least two days. Suspected dengue cases were tested by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR), detection of non-structural protein 1 (NS1), anti-DENV immunoglobulin G and M (IgG and IgM) assays.

resultsA total of 350 individuals from 87 households were enrolled. The overall seroprevalence of anti-DENV IgG at enrolment was 19.4% (95% confidence interval [CI] 14.5-25.6) with the highest seroprevalence rate observed in the adult group. Over the 27-month study period from July 2016 to September 2018, a total of 18 suspected dengue cases were reported. Four cases were confirmed by RT-qPCR and serotyped as DENV-1. A fifth case was confirmed by the NS1 assay. The 13 remaining suspected cases were tested negative by these assays. Based on the 5 virologically confirmed cases, symptomatic dengue incidence proportion of 1.4% (95%CI 0.5-3.8) was estimated. No severe cases or hospitalizations occurred during the study.

conclusionCommunity-based active surveillance was shown as efficient to detect symptomatic dengue cases. CLINICAL

trial registrationNCT02766088.

Indexed as

DengueDengue VirusAdolescentAdultAntibodies, ViralChildChild, PreschoolFemaleHumansImmunoglobulin GImmunoglobulin MIncidenceInfantMaleMexicoMiddle AgedAntibodies, ViralImmunoglobulin GImmunoglobulin M

Identifiers

PMID33951076
PMCPMC8099064
OpenAlexW3157388970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.